Abstract 80P
Background
The standard treatment for glioblastoma multiforme involves surgery followed by temozolomide (TMZ) treatment. However, many patients develop TMZ resistance either due to autophagic clearance of unwanted materials or reversal of TMZ-induced DNA alterations by methyl guanine o-methyl transferase. Additionally, other drugs are often ineffective because they cannot cross the blood-brain barrier (BBB). Hence, our objective is to repurpose FDA-approved drugs capable of crossing BBB and regulating autophagic pathways.
Methods
We identified differentially expressed genes regulating cellular processes in GBM, and used the Connectivity-MAP (C-Map) database to identify potential drugs, capable of reversing differentially expressed autophagy-associated genes. Following in-silico screening, we conducted cytotoxicity assays with selected drugs to evaluate IC50 values of drugs in 2-D and 3-D models. Additionally, immunoblotting and IF were performed to examine protein expression. Furthermore, we employed MDC staining to identify autophagic vacuoles, Annexin-PI to quantify apoptotic cells.
Results
Analysing GEO dataset, we identified top 10 dysregulated genes. Most downregulated genes were calcium signaling, while upregulated ones were PI3-Akt pathway. After identifying key genes and associated pathways, we used C-Map to identify top 5 drugs with high connectivity scores and BBB penetrance. They were assessed in vitro for their potential against GBM. Among them, Doxylamine and Gemfibrozil exhibited the best cytotoxicity, surpassing the standard drug TMZ. These drugs also hindered autophagic flux, verified by increased p62 and LC3B II proteins. Overexpression of PERK and CHOP confirmed ER stress-induced apoptosis. Furthermore, inhibition of Calmodulin, Calreticulin, and Calnexin post-drug-stress influenced the calcium signaling pathway. AnnexinV-PI assay demonstrated that increased ER stress and subsequent restriction of autophagic flux led to cell death.
Conclusions
Our research highlighted that doxylamine and gemfibrozil could serve as potential alternatives to TMZ for inducing apoptosis, by inhibiting autophagy, inducing ER stress, and generating ROS.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Indian Council of Medical Research (ICMR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - Whole exome sequencing reveals high frequency of Notch pathway mutations in Indian breast cancer cases
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract